AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advan
Go back to AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advan| AbbVie (NYSE: ABBV) | Delayed: 264.02 +1.51 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.51 | 52 Week High | $68.12 | |||
| Open | $262.61 | 52 Week Low | $50.71 | |||
| Day High | $264.62 | P/E | 57.27 | |||
| Day Low | $260.88 | EPS | $4.61 | |||
| Volume | 3,509,909 | |||||
